BLACKSBURG, VA July 15, 2017 —The Roanoke-Blacksburg Technology Council (RBTC) recognized a talented group of companies and individuals at its annual TechNite awards banquet, which was held at the Hotel Roanoke & Conference Center on April 21, 2017. TechNite is an annual celebration of the Roanoke – Blacksburg region’s technology community.

“The Innovator Award recognizes an individual, a group of individuals, company, or other organization that sets the standard for thought leadership and innovation in their respective field,” says RBTC President Robert McAden. “By definition, they are doing something new or different, and they are doing it well. Their innovation represents a significant technological breakthrough.”

Landos Biopharma (LANDOS) founder, Josep Bassaganya-Riera, won the 2017 RBTC’s Innovator of the Year award during its 18th annual TechNite Awards Dinner April 21. Bassaganya-Riera is a serial entrepreneur who founded three biotech companies, including LANDOS. He has a demonstrated track record of successfully leveraging advanced informatics and computational modeling to accelerate the discovery, development, and commercialization of innovative technologies into marketable products.

“My resolve to transform healthcare is the driving force behind the success we achieve in LANDOS. By focusing on a unique iterative integration of large-scale clinical record mining, informatics analyses and computer modeling, we are making tangible progress toward the personalized treatment of diseases, such as the development of BT-11 as a safer, more effective oral therapeutic for inflammatory bowel disease. It is a distinct honor and a privilege to be in the company of so many influential leaders and innovators who strive for progress in their fields and dig to find the answers that improve our society as a whole,” says Bassaganya-Riera, LANDOS President and CEO. “Transformative innovation is only possible with the unwavering resolve, hard work, and dedication of an amazing group of individuals. I am proud that the Landos team shares a vision for the future of precision medicine and health.”

Bassaganya-Riera discusses his innovative vision for precision medicine during Virginia Tech’s most recent TEDx event. The team’s resolve to make groundbreaking contributions to health has brought them one step closer to the next generation of human clinical trials that capture human diversity and variation, enabling smarter, faster, more accurate and precise decisions for personalized, predictive medicine.

In one of its largest yearly gatherings to recognize the area’s technology community, the RBTC recognized influential leaders in business and innovation. Bassaganya-Riera was one of dozens of nominees announced for awards that include STEM education, leadership, entrepreneurship and innovation.

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract

for treatment of inflammatory bowel disease (IBD) and is in Phase 1 clinical testing for Crohn’s disease and ulcerative colitis. Landos also has a robust pipeline of compounds for other autoimmune diseases. For more information, please visit or contact [email protected] or follow us @Landosbio.

Company Contacts:

Landos Biopharma:

Josep Bassaganya-Riera


[email protected]

For Media Requests:

Sharon Correia

LaVoieHealth Science


[email protected]